0001171843-18-008539.txt : 20181221 0001171843-18-008539.hdr.sgml : 20181221 20181221171017 ACCESSION NUMBER: 0001171843-18-008539 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20181221 FILED AS OF DATE: 20181221 DATE AS OF CHANGE: 20181221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aeterna Zentaris Inc. CENTRAL INDEX KEY: 0001113423 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38064 FILM NUMBER: 181250434 BUSINESS ADDRESS: STREET 1: C/O STIKEMAN ELLIOTT LLP STREET 2: 1155 RENE-LEVESQUE BLVD. WEST, 41ST FLR CITY: MONTREAL STATE: A8 ZIP: H3B 3V2 BUSINESS PHONE: 843-900-3201 MAIL ADDRESS: STREET 1: C/O STIKEMAN ELLIOTT LLP STREET 2: 1155 RENE-LEVESQUE BLVD. WEST, 41ST FLR CITY: MONTREAL STATE: A8 ZIP: H3B 3V2 FORMER COMPANY: FORMER CONFORMED NAME: AETERNA LABORATORIES INC DATE OF NAME CHANGE: 20000503 6-K 1 f6k_122118.htm FORM 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2018

Commission File Number: 0-30752

Aeterna Zentaris Inc.
(Translation of registrant's name into English)

315 Sigma Drive, Suite 302D Summerville, South Carolina, USA 29486
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-______.

On December 21, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated December 21, 2018

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Aeterna Zentaris Inc.
		(Registrant)


Date: December 21, 2018		/s/ MICHAEL V. WARD
		Michael V. Ward
		CEO

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Aeterna Zentaris Settles Dispute with David Dodd and Philip Theodore

CHARLESTON, S.C., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc., (NASDAQ:AEZS) (TSX: AEZS) has settled its previously disclosed litigation in South Carolina and Canada with former officers of the Company, David Dodd and Philip Theodore. As part of that settlement, the Company has agreed to make a settlement payment to Mr. Dodd in the amount of $775,000.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an oral ghrelin receptor agonist, to be administered in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris is a party to a license and assignment agreement with a subsidiary of Novo Nordisk A/S to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.zentaris.com.

Contact:

Leslie Auld
Chief Financial Officer
Aeterna Zentaris Inc.
IR@aezsinc.com
843-900-3201